Schizophrenia Therapeutics Pipeline Assessment | Clinical and Non-Clinical Studies, Emerging Therapies, Treatment Algorithm, and Key Companies | Delveinsight

DelveInsight assessed more than 70+ companies are working on developing 70+ pipeline therapies in the Schizophrenia Pipeline landscape.

"Schizophrenia Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Schizophrenia Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Request for Sample Report:
https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Schizophrenia Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the Schizophrenia Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Schizophrenia treatment.
Schizophrenia key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Schizophrenia Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Schizophrenia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF: https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Schizophrenia Therapeutics Analysis
Globally, there are approx. 70+ key companies which are developing therapies for Schizophrenia. Otsuka Pharmaceutical is leading the therapeutics segment, with its therapeutic candidate in the most advanced stage of clinical development, i.e., phase III.

Some of the leading companies in the Schizophrenia Market include:
• Otsuka Pharmaceutical
• Gedeon Richter Ltd.
• Neurocrine Bioscience
• Takeda Pharmaceutical Company
• Memory Pharmaceuticals
• Hoffmann-La Roche
• H. Lundbeck
• Organon and Co
• Meiji Seika Pharma Co., Ltd.
• SK Life Science, Inc.
• Novartis Pharmaceuticals
• Vanda Pharmaceuticals
• Alkermes, Inc.
• Solvay Pharmaceuticals
• Sumitomo Dainippon Pharma Co., Ltd.
• Mitsubishi Tanabe Pharma Corporation
• SyneuRx International (Taiwan) Corp
• BioXcel Therapeutics Inc
• Cognitive Research Corporation
• Amarex Clinical Research
• Forum Pharmaceuticals Inc
• Amneal Pharmaceuticals, LLC
• Accutest Research Laboratories (I) Pvt. Ltd.
• Eli Lilly and Company
• Johnson & Johnson Pharmaceutical Research & Development, L.L.C
• Janssen, LP
• Delpor, Inc.
• Cerevel Therapeutics, LLC
• Zogenix, Inc.
• Reviva Pharmaceuticals
• Alkermes, Inc.
• Karuna Therapeutics
And Several Others.

Schizophrenia Therapies covered in the report include:
• Ulotaront (Otsuka Pharmaceutical)
• Luvadaxistat (Takeda)
• CY6463 (Cyclerion Therapeutics)
• AVP 786 (Avanir Pharmaceuticals)
And many more

DelveInsight's report covers around 70+ products under different phases of clinical development like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request the Sample PDF to Get a more in-depth Assessment: https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Schizophrenia Current Treatment Patterns
4. Schizophrenia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Schizophrenia Late Stage Products (Phase-III)
7. Schizophrenia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Schizophrenia Discontinued Products
13. Schizophrenia Product Profiles
14. Schizophrenia Key Companies
15. Schizophrenia Key Products
16. Dormant and Discontinued Products
17. Schizophrenia Unmet Needs
18. Schizophrenia Future Perspectives
19. Schizophrenia Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at: https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.